ReproCell Stock

ReproCell ROCE

The Return on Capital Employed (ROCE) of ReproCell (4978.T) as of Sep 4, 2026 is -1.45 %. In the previous year, Return on Capital Employed (ROCE) was -4.92 % — a change of -70.53% (higher).

ROCE

-1.45 %

YoY

-70.53%

Last updated:

In 2026, ReproCell's return on capital employed (ROCE) was -1.45 %, a -70.53% increase from the -4.92 % ROCE in the previous year.

The ReproCell ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-16.42 JPY
Jan 1, 2019
-11.05 JPY
Jan 1, 2020
-15.02 JPY
Jan 1, 2021
-19.46 JPY
Jan 1, 2022
-8.92 JPY
Jan 1, 2023
-4.70 JPY
Jan 1, 2024
-4.92 JPY
Jan 1, 2025
-1.45 JPY
The ReproCell ROCE history
YEARROCEYoY
-1.45 %-70.53%
-4.92 %+4.72%
-4.70 %-47.31%
-8.92 %-54.15%
-19.46 %+29.57%
-15.02 %+35.97%
-11.05 %-32.70%
-16.42 %+28.10%
-12.82 %-9.08%
-14.10 %+34.84%
-10.45 %+482.10%
-1.80 %
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling ReproCell's Return on Capital Employed (ROCE)

ReproCell's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ReproCell's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ReproCell's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ReproCell’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ReproCell stock

Return on Capital Employed (ROCE) of ReproCell is -1.45 % in 2026.

Return on Capital Employed (ROCE) of ReproCell changed from -4.92 % to -1.45 %, representing a -70.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) ReproCell since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — ReproCell

All Key Metrics — ReproCell